These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38899203)

  • 1. Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers.
    Lee SA; Riella LV
    Kidney Int Rep; 2024 Jun; 9(6):1601-1613. PubMed ID: 38899203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management.
    Fatima A; Rasool S; Devi S; Talha M; Waqar F; Nasir M; Khan MR; Ibne Ali Jaffari SM; Haider A; Shah SU; Sapna F; Varrassi G; Khatri M; Kumar S; Mohamad T
    Cureus; 2023 Sep; 15(9):e46243. PubMed ID: 37908957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data.
    Mittal N; Sehray V; Mittal R; Singh S
    Eur J Pharmacol; 2021 Sep; 907():174320. PubMed ID: 34246651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
    Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
    Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors: Beyond glycemic control.
    Hasan I; Rashid T; Jaikaransingh V; Heilig C; Abdel-Rahman EM; Awad AS
    J Clin Transl Endocrinol; 2024 Mar; 35():100335. PubMed ID: 38525377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
    Yaribeygi H; Butler AE; Atkin SL; Katsiki N; Sahebkar A
    J Cell Physiol; 2018 Jan; 234(1):223-230. PubMed ID: 30076706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.
    Rabizadeh S; Nakhjavani M; Esteghamati A
    Int J Endocrinol Metab; 2019 Apr; 17(2):e84353. PubMed ID: 31372172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
    Herat LY; Matthews VB; Magno AL; Kiuchi MG; Carnagarin R; Schlaich MP
    Expert Opin Pharmacother; 2020 Jul; 21(10):1157-1166. PubMed ID: 32301361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes.
    Vlasschaert C; Sidhu B; Silver SA
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):361-368. PubMed ID: 33767064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists.
    Myasoedova VA; Bozzi M; Valerio V; Moschetta D; Massaiu I; Rusconi V; Di Napoli D; Ciccarelli M; Parisi V; Agostoni P; Genovese S; Poggio P
    Antioxidants (Basel); 2023 Dec; 13(1):. PubMed ID: 38275636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
    Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1481-1490. PubMed ID: 31377891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease.
    Masuda T; Nagata D
    Hypertens Res; 2023 May; 46(5):1195-1201. PubMed ID: 36849579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].
    Schechter M; Mosenzon O
    Harefuah; 2021 Oct; 160(10):671-678. PubMed ID: 34689438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement.
    Alsereidi FR; Khashim Z; Marzook H; Gupta A; Al-Rawi AM; Ramadan MM; Saleh MA
    Curr Probl Cardiol; 2024 May; 49(5):102524. PubMed ID: 38492622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.